Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen

- Results from interim analysis expected by mid-2022 - NDA filing to potentially follow by year-end 2022 CARLSBAD, Calif., July 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). The company has exceeded the enrollment target in NEURO-TTRansform and expects to register more than 160 patients in the study.

The release as fetched from its publisher. ionis.com ↗